Also listed under Endocrine Gland Neoplasms, Pancreatic Diseases
ClinicalTrials.gov term: Pancreatic Neoplasms
112 trials changed in the last 30 days: 2 stopped, 53 with notable changes, 57 with minor changes only.
Trial terminated
Also in this update: Final enrollment: 14 participants (planned 135)
Boehringer IngelheimPhase 1 NCT06882746 Registry history of NCT06882746 on ClinicalTrials.gov (opens the registry)
Trial status changed: Active, Not Recruiting → Suspended
Also in this update: Primary and study completion pushed from Jun 2026 to Mar 2027
Weill Medical College of Cornell UniversityNot applicable NCT03623464 Registry history of NCT03623464 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Nov 2027 to Nov 2028
Also in this update: Primary endpoint(s) modified; Enrollment increased: 294 → 344 participants
Jacobio Pharmaceuticals Co., Ltd.Phase 1/2 NCT06973564 Registry history of NCT06973564 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Dec 31, 2025 to Dec 31, 2027
Also in this update: Study completion pushed from Dec 30, 2026 to Dec 31, 2027
Shandong Boan Biotechnology Co., LtdPhase 1 NCT06596915 Registry history of NCT06596915 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Jun 2026 to Mar 2028
Also in this update: Study completion pushed from Dec 2026 to Jun 2028
Eleison Pharmaceuticals LLC.Phase 3 NCT01954992 Registry history of NCT01954992 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Aug 30, 2026 to Aug 30, 2027
Also in this update: Study completion pushed from Oct 30, 2026 to Dec 30, 2027
Impact Biotech LtdPhase 1 NCT05919238 Registry history of NCT05919238 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from May 30, 2026 to Jun 30, 2027
Also in this update: Sponsor changed: Suzhou Transcenta Therapeutics Co., Ltd. to Transcenta Therapeutics (Hangzhou) Co., Ltd.; Study completion pushed from Nov 30, 2026 to Sep 30, 2027
Transcenta Therapeutics (Hangzhou) Co., Ltd.Phase 1/2 NCT04396821 Registry history of NCT04396821 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Jul 16, 2027 to Mar 16, 2029
Also in this update: Enrollment increased: 280 → 392 participants; Interventions modified
AstraZenecaPhase 1/2 NCT06005493 Registry history of NCT06005493 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from May 15, 2027 to Sep 30, 2028
Also in this update: Primary endpoint(s) modified; Interventions modified
Revolution Medicines, Inc.Phase 1/2 NCT06445062 Registry history of NCT06445062 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Dec 31, 2026 to Jun 30, 2027
Ono Pharmaceutical Co., Ltd.Phase 1 NCT06532344 Registry history of NCT06532344 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Dec 31, 2026 to Oct 31, 2027
Also in this update: Enrollment increased: 292 → 473 participants; Study completion pushed from Jun 1, 2027 to Mar 30, 2028
Bicara TherapeuticsPhase 1 NCT04429542 Registry history of NCT04429542 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Jun 2026 to Jun 2027
Baylor Research InstitutePhase 2 NCT04926467 Registry history of NCT04926467 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Jul 2029 to Sep 30, 2030
Also in this update: Enrollment closed, study ongoing
Mayo ClinicPhase 2 NCT04858009 Registry history of NCT04858009 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Sep 2026 to Dec 2027
Also in this update: Study completion pushed from Dec 2026 to Jan 2028
HealthPartners InstitutePhase 2 NCT06605430 Registry history of NCT06605430 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Jun 1, 2031 to Jan 1, 2032
University of MiamiPhase 2 NCT07565155 Registry history of NCT07565155 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Jun 2027 to Apr 2028
Also in this update: Primary endpoint(s) modified; Enrollment increased: 145 → 545 participants
Kestrel Therapeutics, Inc.Phase 1 NCT07458347 Registry history of NCT07458347 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Dec 31, 2026 to Dec 31, 2027
National Cancer Institute (NCI)Phase 2 NCT02465060 Registry history of NCT02465060 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Oct 30, 2026 to Sep 8, 2028
Also in this update: Recruitment opened
National Cancer Institute (NCI)Phase 1/2 NCT07619521 Registry history of NCT07619521 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Dec 31, 2027 to Dec 31, 2028
Also in this update: Enrolling by invitation only; Interventions modified
Ohio State University Comprehensive Cancer CenterNot applicable NCT07619417 Registry history of NCT07619417 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Sep 2026 to Sep 2027
Memorial Sloan Kettering Cancer CenterPhase 1/2 NCT03245541 Registry history of NCT03245541 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
RayzeBio, Inc.Phase 3 NCT05477576 Registry history of NCT05477576 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Trial sites reduced: 42 → 31 locations
RenovoRxPhase 3 NCT03257033 Registry history of NCT03257033 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Aug 31, 2026 to Oct 31, 2026
Astellas Pharma Global Development, Inc.Phase 2 NCT03816163 Registry history of NCT03816163 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Jul 31, 2026 to Dec 31, 2026
Astellas Pharma Global Development, Inc.Phase 1 NCT06396091 Registry history of NCT06396091 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Study completion date changed from estimate of Oct 1, 2026 to Sep 1, 2026; Final enrollment: 1334 participants (planned 1020)
Dana-Farber Cancer InstituteNot applicable NCT05225428 Registry history of NCT05225428 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Jun 30, 2026 to Nov 30, 2026
Also in this update: Enrollment increased: 115 → 160 participants; Study completion pushed from Dec 30, 2026 to Dec 30, 2028
Medicenna Therapeutics, Inc.Phase 1/2 NCT05086692 Registry history of NCT05086692 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Study completion date changed from estimate of Dec 2026 to May 26, 2026
ECOG-ACRIN Cancer Research GroupPhase 2 NCT01824875 Registry history of NCT01824875 on ClinicalTrials.gov (opens the registry)
Trial status changed: Enrolling by Invitation → Active, Not Recruiting
Also in this update: Final enrollment: 119 participants (planned 300)
M.D. Anderson Cancer CenterPhase 1 NCT02600949 Registry history of NCT02600949 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Study completion moved earlier from Dec 2028 to Dec 2027; Primary completion date changed from estimate of Dec 2026 to Aug 20, 2026
Georgetown UniversityPhase 3 NCT05482516 Registry history of NCT05482516 on ClinicalTrials.gov (opens the registry)
Enrollment increased: 285 → 330 participants
ModeX Therapeutics, An OPKO Health CompanyPhase 1/2 NCT06239194 Registry history of NCT06239194 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Study completion moved earlier from Oct 1, 2028 to Feb 17, 2027; Primary completion date changed from estimate of Oct 1, 2027 to Aug 17, 2026
Mayo ClinicPhase 1/2 NCT04605913 Registry history of NCT04605913 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Final enrollment: 16 participants (planned 21)
University of Kansas Medical CenterPhase 1/2 NCT06736717 Registry history of NCT06736717 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Final enrollment: 31 participants (planned 37)
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsPhase 1 NCT05013216 Registry history of NCT05013216 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
John LenehanPhase 1 NCT06393400 Registry history of NCT06393400 on ClinicalTrials.gov (opens the registry)
Enrollment increased: 364 → 404 participants
Astellas Pharma IncPhase 1 NCT07094204 Registry history of NCT07094204 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 16 → 19 locations
SOFIEPhase 3 NCT07217717 Registry history of NCT07217717 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Sep 30, 2026 to Dec 31, 2026
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsPhase 2 NCT02451982 Registry history of NCT02451982 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Jul 2042 to Nov 2042
University of PennsylvaniaPhase 1 NCT07594067 Registry history of NCT07594067 on ClinicalTrials.gov (opens the registry)
Trial status changed: Unknown → Completed
Tanta UniversityNot applicable NCT06539806 Registry history of NCT06539806 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Primary completion date changed from estimate of Sep 30, 2026 to May 19, 2026; Final enrollment: 297 participants (planned 350)
Massachusetts General HospitalNot applicable NCT05470920 Registry history of NCT05470920 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Institut CurieNot applicable NCT05475366 Registry history of NCT05475366 on ClinicalTrials.gov (opens the registry)
Completed without a posted recruiting period
Also in this update: Primary completion date changed from estimate of Dec 3, 2025 to Aug 3, 2025
Peking University First HospitalNot applicable NCT06833658 Registry history of NCT06833658 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
H. Lee Moffitt Cancer Center and Research InstituteNot specified NCT04275557 Registry history of NCT04275557 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 34 → 37 locations
And 2 more changes in the last 30 days
Verastem, Inc.Phase 2 NCT07644559 Registry history of NCT07644559 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Jun 30, 2026 to Nov 30, 2026
Masaryk Memorial Cancer InstituteNot applicable NCT06330441 Registry history of NCT06330441 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 57 → 63 locations
And 2 more changes in the last 30 days
Immuneering CorporationPhase 3 NCT07562152 Registry history of NCT07562152 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 1 → 5 locations
Revolution Medicines, Inc.Phase 3 NCT07805954 Registry history of NCT07805954 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 223 → 230 locations
And 1 more change in the last 30 days
PfizerPhase 2/3 NCT06989437 Registry history of NCT06989437 on ClinicalTrials.gov (opens the registry)
Enrollment increased: 258 → 350 participants
Also in this update: Interventions modified
Phanes TherapeuticsPhase 1/2 NCT05482893 Registry history of NCT05482893 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 13 → 19 locations
And 1 more change in the last 30 days
Revolution Medicines, Inc.Phase 3 NCT07621718 Registry history of NCT07621718 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Dec 18, 2026 to May 15, 2027
Mayo ClinicPhase 2 NCT07285044 Registry history of NCT07285044 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 61 → 82 locations
And 1 more change in the last 30 days
Revolution Medicines, Inc.Phase 3 NCT07491445 Registry history of NCT07491445 on ClinicalTrials.gov (opens the registry)
Enrollment increased: 100 → 120 participants
National Cancer Institute (NCI)Phase 1 NCT06885697 Registry history of NCT06885697 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 74 → 78 locations
Revolution Medicines, Inc.Phase 3 NCT07252232 Registry history of NCT07252232 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 62 → 79 locations
Astellas Pharma Global Development, Inc.Phase 3 NCT07409272 Registry history of NCT07409272 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 11 → 16 locations
Perspective TherapeuticsPhase 1/2 NCT06710756 Registry history of NCT06710756 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 91 → 94 locations
Daiichi SankyoPhase 2 NCT06172478 Registry history of NCT06172478 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 16 → 20 locations
Corcept TherapeuticsPhase 2 NCT07259317 Registry history of NCT07259317 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 17 → 21 locations
Astellas Pharma Global Development, Inc.Phase 1/2 NCT07488676 Registry history of NCT07488676 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 3 → 16 locations
Blueprint Medicines CorporationPhase 1/2 NCT07629960 Registry history of NCT07629960 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 3 → 7 locations
Avacta Life Sciences LtdPhase 1 NCT07454642 Registry history of NCT07454642 on ClinicalTrials.gov (opens the registry)
Trial sites reduced: 23 → 20 locations
AstraZenecaPhase 1 NCT05877599 Registry history of NCT05877599 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 18 → 23 locations
Alliance for Clinical Trials in OncologyNot applicable NCT07059884 Registry history of NCT07059884 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Oct 2, 2026 to Sep 1, 2027
City of Hope Medical CenterPhase 1 NCT02432963 Registry history of NCT02432963 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Aug 18, 2026 to Dec 18, 2026
Shandong Cancer Hospital and InstitutePhase 2 NCT06050317 Registry history of NCT06050317 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Oct 1, 2026 to Oct 5, 2027
Also in this update: Primary completion date changed from estimate of Oct 1, 2026 to Jul 16, 2025; Final enrollment: 68 participants (planned 88)
National Cancer Institute (NCI)Phase 2 NCT04548752 Registry history of NCT04548752 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Sep 2026 to Apr 2028
Beth Israel Deaconess Medical CenterNot specified NCT05973331 Registry history of NCT05973331 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Aug 11, 2026 to Jul 14, 2027
City of Hope Medical CenterNot applicable NCT02293954 Registry history of NCT02293954 on ClinicalTrials.gov (opens the registry)
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Active, Not Recruiting
ENB Therapeutics, IncPhase 1/2 NCT04205227 Registry history of NCT04205227 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Aug 2023); last known: Recruiting
Chongqing Precision Biotech Co., LtdPhase 1 NCT06010862 Registry history of NCT06010862 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
Light Chain Bioscience - Novimmune SAPhase 1 NCT05403554 Registry history of NCT05403554 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since May 2024); last known: Not Yet Recruiting
Rui-hua Xu, MD, PhDPhase 2 NCT06329947 Registry history of NCT06329947 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Jan 2024); last known: Recruiting
N.N. Petrov National Medical Research Center of OncologyPhase 2 NCT06229340 Registry history of NCT06229340 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Dec 2022); last known: Recruiting
Yonsei UniversityPhase 2 NCT05679583 Registry history of NCT05679583 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Aug 2024); last known: Active, Not Recruiting
Anup KasiPhase 1/2 NCT05121038 Registry history of NCT05121038 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Aug 2024); last known: Not Yet Recruiting
West China HospitalNot applicable NCT06541561 Registry history of NCT06541561 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Jul 2021); last known: Not Yet Recruiting
National Taiwan University HospitalNot specified NCT05010226 Registry history of NCT05010226 on ClinicalTrials.gov (opens the registry)
Changed
Registry verification sweep
Changed
| First posted | Trial | Sponsor | Phase |
|---|---|---|---|
| 2026-10-15 | NCT07875920 Phase 1 Study of NW-301V TCR-T Cells in Advanced Solid Tumors With KRAS G12V Mutation | Neowise Biotechnology new | Phase 1 |
| 2026-10-15 | NCT07875465 Intestinal Low-Dose Radiotherapy Combined With Immune Checkpoint Inhibitors in Solid… | Bing Xia new | Phase 2 |
| 2026-10-15 | NCT07875582 Diagnostic Utility of Protein Biomarkers in Pancreatic Ductal Adenocarcinoma | Grigore T. Popa University of Medicine and Pharmacy new | |
| 2026-10-13 | NCT07870421 A Study Looking at Whether a Nutritional Composition Can Help People With Pancreatic… | Nutricia Research new | |
| 2026-09-30 | NCT07850336 Pancreatic Endoscopic Ultrasound-guided RadioFrequency for Inoperable Carcinoma Treatment | Bojan Kovacevic new | |
| 2026-09-24 | NCT07839676 A Prospective Study of Concurrent Hyperthermia, Chemotherapy and Radiotherapy in… | Fernando Pessoa Canarias University new | |
| 2026-09-21 | NCT07831694 Postoperative Outcomes After Partial Duodenopancreatectomy Versus Total Pancreatectomy | Cantonal Hospital of St. Gallen new | |
| 2026-09-18 | NCT07828236 PHASE 1 TRIAL OF Lm-LLO-TT AND GEMCITABINE IN UNRESECTABLE PANCREATIC DUCTAL… | Loki Therapeutics, Inc. new | Phase 1 |
| 2026-09-17 | NCT07825870 Outcomes of Fluoroscopy-Guided Transdiscal Splanchnic Nerve Neurolysis for Upper… | Sahiwal medical college sahiwal new | |
| 2026-09-14 | NCT07817147 CREO - Microwave Ablation Feasibility Study | Banner Health new |
| Early Phase 1 | 41 | |
| Phase 1 | 232 | |
| Phase 1/2 | 195 | |
| Phase 2 | 308 | |
| Phase 2/3 | 24 | |
| Phase 3 | 65 | |
| Phase 4 | 13 |
National Cancer Institute (NCI) (33) · Fudan University (26) · M.D. Anderson Cancer Center (26) · Memorial Sloan Kettering Cancer Center (23) · Ruijin Hospital (19) · Tianjin Medical University Cancer Institute and Hospital (17) · Mayo Clinic (16) · IRCCS San Raffaele (15) · Zhejiang University (15) · Changhai Hospital (14)